Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triamcinolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | CYP2J2 | P51589 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.86 |
| ▸ | AR | P10275 | 2/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | APEX1 | P27695 | 1/20 | 0.86 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.86 |
| ▸ | IKBKB | O14920 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triamcinolone SCHEMBL1884154 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL9863653 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL601461 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL1502196 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL14373318 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL8813577 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL24622562 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL601462 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL22962813 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL4447 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160206749-A1 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | MARINA BIOTECH, INC. (US) | 2016-07-21 | — | — | US | claimed |
| US-20080261304-A1 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-10-23 | — | — | US | claimed |
| US-20060014289-A1 | Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6830758-B2 | Patch containing drug; flexible backing; pressure sensitive adhesive | LECTEC CORPORATION | 2004-12-14 | — | — | US | claimed |
| US-20030077316-A1 | Psoriasis patch | AXOGEN CORPORATION | 2003-04-24 | — | — | US | claimed |
| US-20020192273-A1 | Therapeutic patch useful for the treatment of hemorrhoids | LEC TEC CORPORATION | 2002-12-19 | — | — | US | claimed |
| EP-0231070-B1 | Fluorocarbon blood substitutes | ALLIANCE PHARMA (US) | 1998-06-10 | — | — | EP | claimed |
| US-5080885-A | Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport | ALLIANCE PHARMACEUTICAL CORP. (US) | 1992-01-14 | — | — | US | claimed |
| EP-0231070-A2 | Fluorocarbon blood substitutes | ALLIANCE PHARMACEUTICAL CORP. (US) | 1987-08-05 | — | — | EP | claimed |
| US-20230128252-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4135699-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| EP-3692981-B1 | TOPICAL COMPOSITION FOR USE IN THE TREATMENT OF PSORIASIS | CHEM CURE ASS LLC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-11260063-B2 | Method and compositions for treating psoriasis | CHEM-CURE ASSOCIATES LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-4432964-A | Topical composition containing steroid in two forms released independently from polymeric carrier | ALZA CORPORATION (US) | 1984-02-21 | — | — | US | disclosed |
| US-4304765-A | Ocular insert housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1981-12-08 | — | — | US | disclosed |
| US-4181669-A | A CARBODIIMIDE WITH ACID CATALYSTS AS A CONDENSATION AGENT | AKTIEBOLAGET LEO (SE) | 1980-01-01 | — | — | US | disclosed |
| US-4180504-A | Method for the preparation of esters | AKTIEBOLAGET LEO (SE) | 1979-12-25 | — | — | US | disclosed |
| US-4150120-A | Ophthalmic | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1979-04-17 | — | — | US | disclosed |
| US-4112073-A | Medicinal composition comprising adrenal cortical hormone and thyroid stimulating hormone releasing hormone | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | NR3C1 3463/4885HIF1A 2861/4885CYP3A4 2859/4885 |
| US-20080261304-A1 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | SNRPE, LDLR, SNRPA | NR3C1 905/4885HIF1A 789/4885CYP3A4 4883/4885 |
| US-20160206749-A1 | METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF DOUBLE-STRANDED RNA OR A DOUBLE-STRANDED HYBRID NUCLEIC ACID TO REGULATE GENE EXPRESSION IN MAMMALIAN CELLS | SNRPE, SREBF2, SREBF1 | NR3C1 3285/4885HIF1A 1123/4885CYP3A4 4860/4885 |
| US-20020192273-A1 | Therapeutic patch useful for the treatment of hemorrhoids | PTGIR, PLOD3, PTGIS | NR3C1 2462/4885HIF1A 674/4885CYP3A4 4474/4885 |
| US-20230128252-A1 | PHARMACEUTICAL COMPOSITIONS | SLCO4C1, SLCO1B1, SLCO1A2 | NR3C1 4012/4885HIF1A 3654/4885CYP3A4 38/4885 |
| US-20060014289-A1 | Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells | SNRPE, SREBF2, SREBF1 | NR3C1 3285/4885HIF1A 1123/4885CYP3A4 4860/4885 |
| US-20030077316-A1 | Psoriasis patch | PEF1, ITCH, DSG1 | NR3C1 1592/4885HIF1A 1316/4885CYP3A4 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.